Analyst Price Target Update on Synthetic Biologics Inc (NYSEMKT:SYN)

Synthetic Biologics Inc (NYSEMKT:SYN): 4 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $9 in Synthetic Biologics Inc (NYSEMKT:SYN). However, the stock price could fluctuate by $ 0.82 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $10 price target with the lower price estimate is calculated at $8

For this week, the average consensus of the company shares are rated as a Strong Buy.

Synthetic Biologics Inc (NYSEMKT:SYN) witnessed a volatile trading activity on Monday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $1.75 and reached the intraday high at $1.84. The bulls started the profit booking and pushed the shares to intraday low of $1.73. The trading session was marked by a volume range of 855,457 shares exchanging hands. The 52-week high of the shares is $4.32 and the 52-week low is $0.93. The market cap of the company stands at $164 million and there are 90,826,752 shares in public circulation.

Synthetic Biologics, Inc. is a clinical-stage biotechnology company. The Company is developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase II oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.